Melanotan II (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Melanotan II (often abbreviated MT-II) is a synthetic cyclic heptapeptide modelled on α-melanocyte-stimulating hormone (α-MSH). The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed in the documented literature, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers 100 mcg of material, so 5 units corresponds to 500 mcg. That round ratio keeps the arithmetic clean across every titration step below.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow-loading approach documented in the early Phase I pigmentation work, where small daily amounts were stepped up over the first weeks to limit nausea and flushing before settling into a lower maintenance cadence.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, which limits foaming.
3. Roll or swirl gently until the powder fully dissolves. Do not shake; vigorous agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Front-Loaded) Schedule

Some documented protocols compress the loading block by holding the 1 mg daily ceiling from the outset rather than stepping up over three weeks. This reaches visible pigmentation faster but raises the chance of early nausea and flushing, so it is presented only as a comparative reference.

Supplies Needed

• Melanotan II vials (30 mg): ~2 vials cover an 8-week loading run; ~3 vials for a 12-week run; ~4 vials for a 16-week run including maintenance.
• Insulin syringes (U-100, 1 mL, 29–31 G): ~56 for an 8-week daily schedule, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle reconstitutes ~3 vials; two bottles cover a full 16-week run.
• Alcohol swabs: two to three 100-count boxes for an 8–16 week schedule.

Protocol Overview

• Research goal: model UV-independent melanogenesis via melanocortin receptor activation.
• Schedule: daily subcutaneous administration during loading, tapering to 1–2× weekly maintenance.
• Dose band: 250–1000 mcg daily loading; 500–1000 mcg weekly maintenance.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Start at the 250 mcg step and raise by ~250 mcg per week to let tolerability settle before reaching the 1 mg ceiling.
• Dosing in the evening is commonly noted in the literature because transient nausea and flushing tend to peak shortly after administration.
• Once the target pigmentation endpoint is reached, drop to the lower maintenance frequency rather than continuing daily exposure.
• Hold the per-injection amount at or below 1 mg; the upside in the documented data plateaus well before the toxic range.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within roughly one to two weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and keep the vial shielded from direct light.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Because per-injection volumes are very small (often under 0.10 mL), measure carefully on the unit scale to avoid overdraw.
• Rotate handling technique to keep the stopper intact across many draws.
• Document each draw — date, volume, remaining material — for reproducibility.

How Melanotan II Works

Melanotan II is a cyclic heptapeptide analog of α-MSH that binds the melanocortin receptor family, with notable activity at MC1R and MC4R. Activation of MC1R on melanocytes drives eumelanin synthesis, producing skin darkening that does not depend on ultraviolet exposure; the effect accumulates over successive daily injections during the loading phase. Activity at MC4R, a central receptor involved in appetite and sexual function, accounts for the appetite-suppressant and libido-related effects reported alongside pigmentation in the literature.

Reported Benefits & Side Effects

Benefits noted in the literature

• Increased cutaneous pigmentation without UV exposure, typically visible after roughly 5–10 daily injections.
• Sustained pigmentation maintained on the lower 1–2× weekly maintenance cadence.
• Appetite reduction attributed to central MC4R activation.
• Reports of increased libido and spontaneous erections via the same MC4R pathway.

Side effects reported

• Dose-dependent nausea, most pronounced shortly after injection.
• Facial flushing and a sensation of skin warmth.
• Reduced appetite and mild fatigue.
• Injection-site reactions, and darkening or changes in existing moles, which has prompted melanoma-monitoring concerns.
• At higher-than-documented doses, serious systemic toxicity including rhabdomyolysis and cardiovascular effects.

Injection Technique (Reference Only)

• Use a 1 mL U-100 insulin syringe (29–31 gauge, ½-inch needle) and clean both the vial stopper and the site with alcohol swabs, letting them air-dry.
• Pinch a ~1-inch skin fold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then withdraw and apply light pressure.
• Rotate sites systematically across abdomen, thighs and upper arms, and dispose of sharps in an approved container.

References

Related Protocols